The known late‐stage lung cancer biomarkers related to immunotherapy, including driver mutations, PD‐L1, and TMB levels, were also evaluated for their effects on the stage IA NSCLC TME. The gene discussed is CD274; the disease is non-small cell lung carcinoma.